Ranibizumab

Ranibizumab Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension (one patient). After three to eight injections over three to twelve months, seven patients experienced IOP elevation, and one patient developed IOP elevation at four follow-up. The patients were treated with acetazolamide, brimonidine/ timolol, apraclonidine, brimonidine and/or pilocarpine. Six patient underwent selective laser trabeculoplasty, trabeculectomy, cyclodiode laser surgery or combined phacoemulsification and viscocanalostomy. After the procedure, their IOP had improved. Six patients were continued on ranibizumab injections after the procedure and their IOP remained controlled. Author comment: "Intravitreal ranibizumab injections are associated with sustained [intraocular pressure] elevation in some eyes." Reis GMSM, et al. Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration. Journal of Current Glaucoma Practice 11: 3-7, No. 1, Jan-Apr 2017. Available from: URL: http://doi.org/10.5005/jp-journals-10008-1213 - Australia 803323602 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ranibizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/ranibizumab-EBoxkWT2Ri
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46973-z
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension (one patient). After three to eight injections over three to twelve months, seven patients experienced IOP elevation, and one patient developed IOP elevation at four follow-up. The patients were treated with acetazolamide, brimonidine/ timolol, apraclonidine, brimonidine and/or pilocarpine. Six patient underwent selective laser trabeculoplasty, trabeculectomy, cyclodiode laser surgery or combined phacoemulsification and viscocanalostomy. After the procedure, their IOP had improved. Six patients were continued on ranibizumab injections after the procedure and their IOP remained controlled. Author comment: "Intravitreal ranibizumab injections are associated with sustained [intraocular pressure] elevation in some eyes." Reis GMSM, et al. Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration. Journal of Current Glaucoma Practice 11: 3-7, No. 1, Jan-Apr 2017. Available from: URL: http://doi.org/10.5005/jp-journals-10008-1213 - Australia 803323602 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off